92P PD-L1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer in PD-L1 positive patients: A safety data network meta-analysis

Abstract

Immunotherapy (IT) targeting programmed cell death-1 receptor (PD-1) and programmed death-ligand 1 (PD-L1) has considerably improved the overall survival of non-small cell lung cancer (NSCLC) patients. This network meta-analysis (MA) evaluates the safety of first-line (1L) PD-L1 inhibitors monotherapy in advanced NSCLC patients compared to platinum-based chemotherapy (CT). We also compared the risk of Adverse Events (AEs) according to programmed cell death-1 receptor (PD-1) or PD-L1 inhibitors therapy.